Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | IDO1 | P14902 | 3/20 | 0.55 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601112 | 0.76 | NOS1 (0.61) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL2619246 | 0.75 | NOS1 (0.55) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL18193497 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277055 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL4314318 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL277054 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL5951586 | 0.74 | AXL (0.63) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL155255 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL476854 | 0.74 | NOS1 (1.00) | NOS1AXLIDO1METAP2JAK2 | |
| SCHEMBL28633087 | 0.74 | NOS1 (0.59) | NOS1AXLIDO1METAP2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | claimed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-01 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7652008-B2 | 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2133343-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | NISSAN CHEMICAL INDUSTRIES, LTD (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2003135-A2 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005075477-A1 | ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | NOS1 1819/4885AXL 2506/4885IDO1 2850/4885 |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | NOS1 3158/4885AXL 68/4885IDO1 902/4885 |
| US-20100081808-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND | OSTC, EEF1D, SQLE | NOS1 526/4885AXL 3595/4885IDO1 2162/4885 |
| US-20090043100-A1 | Process for Producing Optically Active Chromene Oxide Compound | CYP2C19, CYP2C9, CYP1A2 | NOS1 1019/4885AXL 226/4885IDO1 1481/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | NOS1 2037/4885AXL 2988/4885IDO1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.